INTRODUCTION AND OBJECTIVES: Histone deacetylase (HDAC) inhibitors not only induce histone acetylation but also inhibit molecular chaperones, causing unfolded proteins to accumulate and thereby inducing endoplasmic reticulum (ER) stress. However, the efficacy of HDAC inhibitors as anticancer agents is limited, especially in solid tumors. The HDAC inhibitor entinostat is partly metabolized by CYP3A4, and the human immunodeficiency virus protease inhibitor ritonavir also inhibits CYP3A4. We therefore thought that combining ritonavir with entinostat would kill cancer cells effectively by enhancing entinostat's activity.
INTRODUCTION AND OBJECTIVES: Histone deacetylase (HDAC) inhibitors not only induce histone acetylation but also inhibit molecular chaperones, causing unfolded proteins to accumulate and thereby inducing endoplasmic reticulum (ER) stress. However, the efficacy of HDAC inhibitors as anticancer agents is limited, especially in solid tumors. The HDAC inhibitor entinostat is partly metabolized by CYP3A4, and the human immunodeficiency virus protease inhibitor ritonavir also inhibits CYP3A4. We therefore thought that combining ritonavir with entinostat would kill cancer cells effectively by enhancing entinostat's activity.
METHODS: Renal cancer cells (769-P, 786-O, Caki-2) were treated with ritonavir (20-40 mM) and entinostat (10-20 mM). Cell viability and clonogenicity were assessed by MTS assay and colony formation assay. A murine subcutaneous tumor model was used to evaluate in vivo efficacy. Flow cytometry was used for cell cycle analysis and annexin-V assay. Western blotting was used to evaluate the induction of histone acetylation and ER stress and the expression of cleaved poly(ADP-ribose) polymerase and the autophagy marker light chain (LC) 3-II. Combination indexes were calculated by the Chou-Talalay method.
RESULTS: The combination of entinostat and ritonavir inhibited cancer cell growth synergistically (combination indexes <1) and suppressed colony formation significantly (p <0.05). The combination perturbed the cell cycle, increasing the number of the cells in the sub-G1 fraction (up to 98.2%). Drastic increases in the number of annexin-V positive cells (up to 98.6%) confirmed that the combination induced apoptosis. In murine subcutaneous tumor models using Caki-2 cells, a 10-day treatment with a combination of entinostat (2 mg/kg) and ritonavir (50 mg/kg) was well tolerated and inhibited tumor growth significantly (p <0.05). As expected, entinostat induced histone acetylation in a dose-dependent fashion, and ritonavir enhanced this acetylation synergistically. The combination also synergistically induced ER stress evidenced by increased expression of glucose-regulated protein 78 and endoplasmic reticulum resident protein 44. Interestingly, we also found that entinostat-ritonavir combination increased the expression of LC3-II, confirming that the unfolded protein accumulation due to the combination induced autophagy. CONCLUSIONS: Ritonavir enhanced entinostat's activity, and the combination inhibited renal cancer growth synergistically.
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MP73-11 GINSENOSIDE COMPOUND K ENHANCES TRAIL-MEDIATED RENAL CANCER CELL APOPTOSIS THROUGH CHOP SIGNALING
Yu Ren, Shuaishuai Huang, Xue Wang, Xuping Yao, Guobin Weng*, Ningbo, China, People's Republic of INTRODUCTION AND OBJECTIVES: Molecular target therapy is a new approach to cure renal carcinoma. In the process of cell apoptosis, TRAIL binds to the death receptor 4 (DR4) and 5(DR5), forming a death inducing signaling complex (DISC) complex, thus leading to a subsequent apoptosis process. However, drug resistance of TRAIL is a major roadblock for the application of TRAIL-based cancer therapy, and the mechanisms are poorly understood. Reports have shown Ginsenoside compound K (CK) acted as potential anti-tumor drug in many cancer types. In our study, we investigate the influence of CK on renal cancer cell apoptosis induced by TRAIL, and further explore the potential mechanisms.
METHODS: Cell viability was measured by MTs, with TRAIL treated alone or combined used of CK. Cell apoptosis was evaluated by PI/Annexin V staining and flow cytometer. Furthermore, we use western blot to measure the target protein changes.
RESULTS: In this study, we treated CK alone or in combination with TRAIL in Caki, A498 and ACHN cell lines. We found combined treatment of CK and TRAIL significantly increased cell apoptosis rate compared with TRAIL treated alone ( Figure. 1A, B, C, D) . Furthermore, CK induced DR5 (death receptor 5) expression in a time and concentration manner ( Figure. 1E, F, G) . To our surprise, the CKenhanced TRAIL-mediated cell apoptosis was abrogated by addition of DR5siRNA or CHOP siRNA, but not DR4 siRNA ( Figure. 1H-O) . In addition, we found CK markly inhibited XIAP, surviving, Mcl-1 expression, but have no influence on c-IAP1, c-IAP2, Bcl-2 and Bcl-xl levels (Figure. 1P, Q).
CONCLUSIONS: Our results indicate that CK inhibits the aititumor proteins and up-regulates DR5 expression through CHOP signaling, thus enhancing TRAIL-mediated renal cancer cell apoptosis. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e967
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